FINWIRES · TerminalLIVE
FINWIRES

$VERA

10 stories mentioning VERAUpdated 6d ago

Every FINWIRES story that references VERA, newest first.

What's the latest news on VERA?

Wire

Top Midday Stories: Waystar Reportedly Mulling Potential Sale; Intel-Backed Altera Says Parent Company Files Confidentially for IPO

All three major US stock indexes were down in late-morning trading Tuesday, as Treasury yields continued to rise and investors increasingly expected the Federal Reserve to raise its benchmark interest rate at the conclusion of its two-day meeting on Wednesday.In company news, Waystar (WAY) is considering multiple options, including a potential sale, Reuters reported Tuesday, citing seven sources familiar with the matter. The healthcare software company has hired Evercore (EVR) to advise on the process, the report said. Waystar shares were up 8.1% around midday. Evercore shares were down 2.1%.Silver Lake- and Intel-backed (INTC) Altera said Tuesday its parent company has confidentially submitted a draft registration statement with the Securities and Exchange Commission relating to the proposed public offering of its common stock. Intel shares were up 1.1%.Vera Therapeutics' (VERA) kidney disease treatment Trutakna achieved all prespecified endpoints during a final review of its Origin 3 study, with full US Food and Drug Administration approval expected in 2027, the drugmaker said Tuesday. Vera shares were down 1.9%.Micron Technology (MU) is facing strike threats from a Taiwanese union representing company workers that is seeking a long-term transparent and verifiable profit-sharing mechanism instead of one-off rewards, Reuters reported Tuesday, citing the chairman of the union. Micron shares were up 0.7%.General Motors (GM) said Tuesday it is launching a new user interface for pickup trucks featuring the latest versions of Apple (AAPL) CarPlay and Android Auto, with plans to deliver additional features and system enhancements through wireless software updates. The features will be available first in light-duty pickup trucks like the 2027 Chevrolet Silverado and 2027 GMC Sierra before expanding across its broader portfolio, the company said. General Motors shares were down 2.1%.Price: $26.80, Change: $+1.90, Percent Change: +7.63%

$EVR$GM$INTC$MU$VERA$WAY
Commodities

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as Traders Prepare for Fed Meeting

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2%, and the actively traded Invesco QQQ Trust (QQQ) was 0.1% lower in Tuesday's premarket activity as traders prepare for the Federal Open Market Committee's meeting.US stock futures were also lower, with S&P 500 Index futures down 0.4%, Dow Jones Industrial Average futures slipping 0.5%, and Nasdaq futures retreating 0.4% before the start of regular trading.The New York Federal Reserve's Empire State manufacturing index fell to 7.6 in September from 20.6 in August, compared with a smaller expected decrease to a reading of 15.0 in a survey compiled by Bloomberg.In premarket action, bitcoin was down by 2.7%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 2.7% lower, Ether ETF (EETH) declined 2.7%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was up 1.1%.Power Play:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.3%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) and the iShares US Consumer Staples ETF (IYK) were inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.2%. The VanEck Retail ETF (RTH) and the State Street SPDR S&P Retail ETF (XRT) were inactive.Sysco (SYY) shares were down 2% after the company said late Monday it plans to launch an offering of $1 billion of its shares.Winners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.1%, the Vanguard Health Care Index Fund (VHT) and the iShares US Healthcare ETF (IYH) were inactive. The iShares Biotechnology ETF (IBB) was 0.5% lower.Vera Therapeutics (VERA) stock was 13% higher after the company said its kidney disease drug met all prespecified endpoints in a phase 3 trial final efficacy analysis.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) retreated 0.3%. Direxion Daily Financial Bull 3X Shares (FAS) was down 0.9%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.9% higher.Enova International (ENVA) shares were down 17% after the company withdrew its applications with the Office of the Comptroller of the Currency and the Board of Governors of the Federal Reserve System for the proposed acquisition of Grasshopper Bancorp.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated 0.4%, while the Vanguard Industrials Index Fund (VIS) and the iShares US Industrials ETF (IYJ) were inactive.Forgent Power Solutions (FPS) shares were 8% higher after the company reported higher fiscal Q4 adjusted net income and revenue.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced 0.01%, the iShares US Technology ETF (IYW) was 0.02% higher, and the iShares Expanded Tech Sector ETF (IGM) was inactive. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was inactive, while the iShares Semiconductor ETF (SOXX) rose by 0.9%.Teradyne (TER) stock was 1% higher after the company said it has opened an office in Bengaluru, India, in a bid to expand its footprint in the country.EnergyThe iShares US Energy ETF (IYE) was inactive, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.2%.Shell (SHEL) shares were advancing 0.3% after a similar retreat in the prior session. The company said it has started production at its new grease manufacturing plant in Indonesia with a capacity of up to 12 kilotonnes per year.CommoditiesFront-month US West Texas Intermediate crude oil was up by 1% at $102.41 per barrel on the New York Mercantile Exchange. Natural gas was down 0.6% at $2.88 per 1 million British Thermal Units. The United States Oil Fund (USO) increased by 0.5%, while the United States Natural Gas Fund (UNG) was 1.6% lower.Gold futures for November retreated by 0.7% to $4,322.00 an ounce on the Comex. Silver futures retreated by 0.7% to $63.69 an ounce. SPDR Gold Shares (GLD) was down by 0.1%, and the iShares Silver Trust (SLV) rose by 0.4%.

Dow JonesNasdaq CompositeS&P 500$ENVA$FAS$FAZ$FPS$GLD$IBB$IGM$IYE$IYH$IYJ$IYK$IYW$QQQ$RTH$SHEL$SLV$SOXX$SPY$SYY$TER$UNG$USO$VDC$VERA$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Healthcare Stocks Fall Pre-Bell Tuesday

Healthcare stocks were falling pre-bell Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) slightly down and the iShares Biotechnology ETF (IBB) 0.5% lower.Ascendis Pharma (ASND) will regain exclusive rights to certain drug treatments for metabolic and cardiovascular diseases, including obesity, having terminated a 2024 collaboration deal with Novo Nordisk (NVO), the company said. Shares of Ascendis Pharma were down more than 2% premarket.Vera Therapeutics' (VERA) kidney disease treatment Trutakna achieved all prespecified endpoints during a final review of its Origin 3 study, with full US Food and Drug Administration approval expected in 2027, the drugmaker said. Vera Therapeutics stock was up more than 14% pre-bell.Ocular Therapeutix (OCUL) shares were up more than 2% after the company said its marketing application for Axpaxli, its experimental treatment for wet age-related macular degeneration, remains on track for submission in Q4 following its meeting with the US Food and Drug Administration.

$ASND$IBB$NVO$OCUL$VERA$XLV
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1.4%.In corporate news, Vertex Pharmaceuticals (VRTX) agreed to buy endocrine disease drugmaker Crinetics Pharmaceuticals (CRNX) for a total equity value of about $10 billion. Crinetics shares jumped 98%, and Vertex was down 1.2%.Eli Lilly (LLY) Canada said Tuesday that Health Canada has approved Mounjaro for pediatric patients aged 10 to 17 with type 2 diabetes. Lilly shares rose 2.7%.Vera Therapeutics' (VERA) Trutakna has been approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy, the US Food and Drug Administration said in a Tuesday statement. Vera Therapeutics shares jumped by more than 7%.AstraZeneca (AZN) has signed an agreement to access Helix's genomic datasets to support research for drug discovery and development, Helix said Tuesday. AstraZeneca shares added 1.4%.

$AZN$CRNX$LLY$VERA$VRTX
Sectors

Sector Update: Healthcare

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 1.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1.2%.In corporate news, Vera Therapeutics' (VERA) Trutakna has been approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy, the US Food and Drug Administration said in a Tuesday statement. Vera Therapeutics shares jumped past 7%.

$VERA
Insider Trading

Vera Therapeutics Insider Sold Shares Worth $701,769, According to a Recent SEC Filing

Marshall Fordyce, Director, President, and CEO, on June 23, 2026, sold 18,500 shares in Vera Therapeutics (VERA) for $701,769. Following the Form 4 filing with the SEC, Fordyce has control over a total of 420,274 Class A common shares of the company, with 198,244 shares held directly and 222,030 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1831828/000185945326000008/xslF345X05/form4-06242026_080643.xml

$VERA
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) dropped 2.9%.In corporate news, Vera Therapeutics (VERA) said Tuesday it aligned with the US Food and Drug Administration on a revised analysis plan for its phase 3 Origin trial of atacicept in adults with IgA nephropathy. Its shares fell past 7%.Abivax (ABVX) faces an increasing risk of black box warning for obefazimod due to malignancies reported from a recent trial, Wedbush Securities said in a note. Abivax shares fell 43%.Heron Therapeutics (HRTX) shares dropped 42% after the company said the US District Court for the District of Delaware has ruled that claims in two of its Cinvanti injectable emulsion patents are invalid.Praxis Precision Medicines' (PRAX) shares lost 20% after it reported late Monday that its phase 2/3 trial assessing vormatrigine to treat focal onset seizures failed to meet its primary endpoint of percent change in monthly seizure frequency from baseline.

$ABVX$HRTX$PRAX$VERA
Sectors

Sector Update: Healthcare

Healthcare stocks declined late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) dropped 2.9%.In corporate news, Vera Therapeutics (VERA) said Tuesday it aligned with the US Food and Drug Administration on a revised analysis plan for its phase 3 Origin trial of atacicept in adults with IgA nephropathy. Its shares fell past 6%.

$VERA
Wire

Vera Therapeutics Aligns With FDA on Earlier Atacicept Analysis to Support Potential Full Approval

Vera Therapeutics (VERA) said Tuesday it aligned with the US Food and Drug Administration on a revised analysis plan for its phase 3 Origin trial of atacicept in adults with IgA nephropathy.The biotechnology company said estimated glomerular filtration rate results from the trial are now expected in Q3. Pending those results, Vera plans to submit a supplemental biologics license application for full approval in Q4.Vera said the FDA alignment was supported by phase 2b Origin trial results showing significant reductions in proteinuria, stabilization of kidney function and a placebo-comparable safety profile, while its phase 3 Origin trial met its primary endpoint and remains ongoing to evaluate eGFR changes.Atacicept has received FDA Breakthrough Therapy Designation for IgAN, and Vera is also studying the drug in other kidney diseases, with enrollment completed in a separate dose-ranging study, the company said.Shares of Vera Therapeutics were down more than 6% in Tuesday trading.Price: $31.76, Change: $-2.18, Percent Change: -6.42%

$VERA
Insider Trading

Vera Therapeutics Insider Sold Shares Worth $1,011,051, According to a Recent SEC Filing

Marshall Fordyce, Director, President, and CEO, on April 14, 2026, sold 22,951 shares in Vera Therapeutics (VERA) for $1,011,051. Following the Form 4 filing with the SEC, Fordyce has control over a total of 457,274 Class A common shares of the company, with 235,244 shares held directly and 222,030 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1831828/000185945326000006/xslF345X05/form4-04152026_080434.xml

$VERA

Track with the FINWIRES app suite